Primary objective
* To create a data and bio-specimen repository to enhance both safety and efficacy of immunotherapy
Secondary objective
* Identify biomarkers that may predict GI toxicity in cancer patients undergoing immunotherapy
* Define the clinical course of intestinal inflammation and identify genetic factors of therapeutic response to GI medications
* Analyze genotype-phenotype correlations in GI side effects in patients undergoing cancer immunotherapy
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of cancer
Currently undergoing or have undergone immunotherapy
You may not be if
History of a total colectomy
History of inflammatory bowel disease (either ulcerative colitis or Crohn's disease)
History of colitis on chemotherapy
Clareo Health | GI Complications in Cancer Immunotherapy Patients
